Meta expands AI ambitions with mega deals

Meta Platforms is deepening its artificial intelligence ambitions with a series of high-value deals and infrastructure ...

Pak-EPA unveils landmark plan to tackle air pollution, smog in Islamabad

The Pakistan Environmental Protection Agency (Pak-EPA) has announced a sweeping new Vehicular Emission Control ...

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in ...

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

Subcutaneous RYBREVANT® (amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational study build on the strength of the data for amivantamab in ...

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating ...